je.st
news
Tag: biopharma
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOXA
2015-12-14 15:57:54| Biotech - Topix.net
TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. . Cephalon was subsequently acquired by Teva.
Tags: million
payment
receives
milestone
Galena Biopharma Announces Departure of Chief Financial Officer
2015-12-11 20:57:30| Biotech - Topix.net
Galena Biopharma, Inc. , a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the departure of the Company's Chief Financial Officer , Mr. Ryan Dunlap, effective December 31, 2015. Mr. Dunlap was unable to relocate his family to the new Company headquarters in San Ramon, California and, therefore, has resigned as of the end of the year.
Tags: financial
chief
officer
departure
Galena Biopharma Raised to "Outperform" at Oppenheimer
2015-11-15 17:14:57| Biotech - Topix.net
The brokerage currently has a $4.00 price target on the biotechnology company's stock. Oppenheimer's target price suggests a potential upside of 166.67% from the company's previous close.
Tags: raised
outperform
oppenheimer
biopharma
Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at...
2015-11-06 19:09:55| Biotech - Topix.net
Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition SAN RAMON, Calif., Nov. 6, 2015 -- Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the final data from the Company's GALE-401 Phase 2 proof-of-concept clinical trial will be presented at the upcoming 57th American Society of Hematology Annual Meeting and Exposition in Orlando, FL.
Galena Biopharma to Present GALE-302 Preliminary Immunological Data...
2015-10-22 21:17:07| Biotech - Topix.net
Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences SAN RAMON, Calif., Oct. 22, 2015 -- Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's NeuVax and GALE-301 and GALE-302 clinical programs will be presented at two upcoming medical conferences.
Tags: data
present
preliminary
immunological
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »